The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I may well be wrong, but after recent volume I don't think DSM can have many left to sell. At end Jan they had 415k, or 2.52%. Am just wondering if they wanted to close out by 31 March...financial year end. If so, then they would need to be out by tomorrow close. IMO DSM is only thing holding this share back, if I am right, would expect strong performance next week
I think I know the reason for the current weakness in the share price. Downing LLP are closing down and as such liquidating their positions. The last I saw was that they held just over 5% of Arecor, but that was from over a year ago and they have been selling for some time now. I do not know how many they have left, but I believe this is an opportunity to either add or take a position in the company at, in my opinion, bargain basement prices. I do not believe the share would be at current levels but for this special situation.
I bought 9,000 @ 166.88 just after opening, not showing ...
I have no idea why, but there must be a large seller. All the volume in recent days have been buys...I bought some this morning, but the price is not moving. Time was that it was v illiquid, but I think at least 25k has been bought over the week and the price has not moved.
Thank you very much
Hi Numptypi,
Could you please give me the gist of the mail article from Saturday, I cant find anything online on it?
May be wrong, but are we not due a trading update before the end of the month, so either either tomorrow or early next week. There appears to be a bit of buying at this level, so maybe the update will be positive and no mention of another cash raise.
The current share price makes no sense whatsoever. On 6th July it announced license deal with Lyell Immunopharma, shares closed at $4.39, on 10th July it announced license deal with Vittoria Biotherapeutics, shares closed at Vittoria Biotherapeutics $4.99. Today it announces license deal with Prime Medicine, shares currntly trading at $4.495. There have been 3 new deals in the space of 1 month. Maxcyte now has 23 strategic partnerships, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments. When will people wake up to this stock?
They had 4.91% previously, but nonetheless it is positive news
Sale volume is distorted, I have bought stock at 29.57, 29.75 and 29.77 this morning. I think anyone selling here will regret it, Q4 will be v interesting.
As an ex market maker, would say that the profit warning was a known ever since the production problems came to light, and given the recent share performance it is already more than in the price. The outlook is v positive, and I expect the shares to bounce today. Personal opinion is that we have hit the bottom and future is bright.
Unusual selling pressure today, does anyone have any idea as to what is going on?
All today's trades are buys, not sells, I have bought 2k @ 2.53...must be a seller there
God knows why, but think there nay be a seller. All trades at 46.75 and above today are buys… I bought 5k @ 46.75… and some decent buys above 47, but price not moving. Why anyone would sell after 3 broker upgrades beyond me.
I see you have only made 2 posts, both with subtle negative slants. Investors here are in for the long term and believe in the company and its management.
Surely the seller must be nearly finished, over 500,000 sold in last couple of days and much much more over last months. My bet is that it is either Janus Henderson or Chelverton Asset Management as anyone with over 5% would have had to disclose. Could be wrong tho.
Although it is a short of just over 0.5%, that still amounts to about 15mln shares according to my calculations...wouldn´t fancy trying to buy that many back without moving the price somewhat. Speculative interest about the PTAB result in May is more likely to produce upside than downside, probably from March onwards. Wouldn´t sleep well being short ahead of it.....